All (n=2440) | No AR (n=787) | Mild AR (n=1400) | Moderate/severe AR (n=253) | p Value | |
---|---|---|---|---|---|
Male (n(%)) | 1296 (53.1) | 384 (48.8) | 751 (53.7) | 160 (63.2) | <0.0003 |
Age (mean±SEM) | 81.6±0.2 | 81.3±0.3 | 81.7±0.2 | 81.2±0.5 | 0.29 |
Height (mean±SEM) | 1.65±0.01 | 1.64±0.01* | 1.65±0.01* | 1.67±0.01 | <0.0001 |
Weight (mean±SEM) | 73.1±0.4 | 73.0±0.6 | 73.1±0.4 | 73.4±1.0 | 0.93 |
BMI (mean±SEM) | 26.9±0.1 | 27.1±0.2 | 26.9±0.2 | 26.3±0.3 | 0.16 |
Logistic EuroSCORE (mean±SEM) | 21.6±0.3 | 20.5±0.5 | 22.3±0.4† | 21.1±0.8 | 0.04 |
Peak pressure gradient (mm Hg) (mean±SEM) | 80.1±0.5 | 76.3±0.9* | 81.5±0.1† | 83.8±1.8† | <0.0001 |
Aortic valve Area (cm2) (mean±SEM) | 0.65±0.01 | 0.66±0.01 | 0.64±0.01 | 0.63±0.01 | 0.13 |
Annulus diameter (mm) (mean±SEM) | 22.56±0.05 | 22.31±0.08* | 22.60±0.06† | 23.19±0.15† | <0.001 |
LVEF>50% | 1472 (60.9) | 491 (63.1) | 842 (60.6) | 139 (55.6) | 0.29 |
LVEF 30–49% | 721 (29.8) | 216 (27.8) | 421 (30.3) | 84 (33.6) | |
LVEF <30% (n(%)) | 223 (9.2) | 71 (9.1) | 125 (9.0) | 27 (10.8) | |
Pulmonary hypertension (PASP >60 mm Hg) (n(%)) | 313 (14.5) | 82 (12.5) | 187 (14.7) | 44 (19.3) | 0.04 |
NYHA I | 50 (2) | 25 (3.2) | 24 (1.7) | 1 (0.4) | 0.05 |
NYHA II | 387 (15.9) | 133 (16.9) | 220 (15.8) | 34 (13.4) | |
NYHA III | 1531 (63.0) | 500 (63.8) | 871 (62.6) | 160 (63.2) | |
NYHA IV (n(%)) | 459 (18.9) | 125 (15.9) | 276 (19.8) | 58 (22.9) | |
Coronary artery disease (n(%)) | 1123 (46.5) | 366 (46.8) | 639 (46.2) | 118(47.0) | 0.94 |
LMS disease (n(%)) | 142 (5.9) | 35 (4.5) | 93 (6.7) | 14 (5.6) | 0.09 |
Porcelain aorta (n(%)) | 566 (23.4) | 232 (29.6) | 278 (20.1) | 56 (22.3) | <0.001 |
Previous cardiac surgery (n(%)) | 745 (30.6) | 235 (29.9) | 439 (31.4) | 71 (28.1) | 0.49 |
Diabetes mellitus (n(%)) | 546 (22.5) | 173 (22.1) | 336 (24.2) | 37 (14.6) | <0.005 |
PVD (n(%)) | 667 (28.4) | 188 (26.2) | 400 (28.9) | 79 (31.4) | 0.19 |
Creatinine (mean±SEM) | 116.6±1.36 | 115.9±2.6 | 117.5±1.8 | 115.2±3.3 | 0.81 |
Previous CVA (n(%)) | 362 (14.9) | 109 (13.9) | 223 (16.1) | 30 (11.9) | 0.12 |
Aortic annulus measurement pre-TAVI | <0.0001 | ||||
TTE | 593 (24.5) | 162 (20.8) | 353 (25.3) | 78 (30.9) | |
TOE | 1698 (70.0) | 562 (72.1) | 973 (69.8) | 163 (64.7) | |
CT | 87 (3.6) | 26 (3.3) | 55 (3.9) | 6 (2.3) | |
MR | 14 (0.6) | 4 (0.5) | 7 (0.5) | 3 (1.2) | |
Angiography (n(%)) | 33 (1.3) | 26 (3.3) | 5 (0.4) | 2 (0.8) |
ANOVA followed by Tukey posthoc test.
χ2 Test likelihood ratio for categorical variables.
*Significant difference against moderate-severe AR group.
†Significant difference against no AR group.
BMI, Body Mass Index; CVA, cardiovascular accident; LMS, left main stem; LVEF, left ventricular EF; MR, magnetic resonance; PASP, pulmonary artery systolic pressure; PVD, peripheral vascular disease; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.